View Older Stories View More Recent Stories

Nov 26, 2025 06:48AM Ascendis Pharma's (ASND) PDUFA Disclosure Removes Near-Term Stock Upside - Stifel
Nov 24, 2025 08:53AM TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)
Nov 17, 2025 04:10PM Wolfe Research Starts Ascendis Pharma (ASND) at Outperform
Nov 17, 2025 04:01PM Ascendis Pharma publishes pivotal trial results for achondroplasia drug
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 13, 2025 06:55AM Ascendis Pharma (ASND) Looks at Decreased FY2025-26 Revenues - Cantor Fitzgerald
Nov 13, 2025 04:04AM Goldman Sachs on Ascendis Pharma (ASND): 'in transition to profitability'
Nov 12, 2025 04:05PM Ascendis Pharma (ASND) Misses Q3 EPS by 72c
Nov 7, 2025 08:31AM Ascendis Pharma reports sustained kidney function improvements with YORVIPATH
Oct 16, 2025 04:06PM Raymond James Starts Ascendis Pharma (ASND) at Strong Buy, PT $271, 'We see a high conviction path to a $4B+ top line'
Oct 13, 2025 07:21AM Cantor Fitzgerald Raises Ascendis Pharma (ASND) PT to $254, Sees Steady New Patient Adds
Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview
Oct 8, 2025 04:01PM Ascendis submits European approval application for achondroplasia drug
Sep 24, 2025 06:00AM Buy weakness in this pharma stock: Wells Fargo
Sep 23, 2025 08:59AM UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
Sep 8, 2025 09:46AM BofA Securities on Ascendis Pharma (ASND): 'well positioned to capture market share'
Aug 20, 2025 08:25AM Ascendis Pharma (ASND) PT Raised to $260 at JPMorgan
Aug 8, 2025 10:13AM Ascendis Pharma (ASND) PT Raised to $203 at Cantor Fitzgerald
Aug 8, 2025 08:40AM Ascendis Pharma (ASND) PT Raised to $230 at RBC Capital
Aug 8, 2025 08:16AM Ascendis Pharma (ASND) PT Raised to $227 at TD Cowen
Aug 8, 2025 05:42AM Ascendis Pharma (ASND) PT Raised to $227 at BofA Securities
Aug 8, 2025 05:29AM Ascendis Pharma (ASND) PT Raised to $285 at Evercore ISI
Aug 8, 2025 05:23AM Ascendis Pharma (ASND) PT Raised to $250 at Goldman Sachs
Aug 7, 2025 04:04PM Ascendis Pharma (ASND) Tops Q2 EPS by 45c
Aug 4, 2025 07:09AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
Jul 28, 2025 07:00AM SKYTROFA receives FDA approval for adult growth hormone deficiency
Jul 14, 2025 04:01PM Ascendis Pharma reports 3-year data on hypoparathyroidism treatment
Jul 8, 2025 02:54PM Ascendis Pharma (ASND) 1K contracts of September 150 puts active
Jul 2, 2025 04:17PM Morgan Stanley Assumes Ascendis Pharma (ASND) at Overweight
Jun 25, 2025 10:13AM UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
Jun 13, 2025 06:00AM Ascendis Pharma (ASND) PT Raised to $224 at Oppenheimer
Jun 10, 2025 10:02AM TD Cowen Reiterates Top Pick and Buy Rating on Ascendis Pharma (ASND)
Jun 10, 2025 09:49AM RBC Capital on Ascendis Pharma (ASND): 'Yorvipath Survey Suggests a Potential Upside To Peak Numbers'
Jun 10, 2025 06:32AM Canaccord Genuity Reiterates Hold Rating on Ascendis Pharma (ASND)
Jun 10, 2025 06:21AM Wells Fargo Reiterates Overweight Rating on Ascendis Pharma (ASND)
Jun 9, 2025 10:55AM Ascendis Pharma (ASND) PT Raised to $216 at BofA Securities
Jun 2, 2025 12:02PM Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities
Jun 2, 2025 08:01AM Ascendis Pharma (ASND) Announces FDA Acceptance of TransCon CNP NDA for Priority Review
May 27, 2025 09:50AM Stifel Reiterates Buy Rating on Ascendis Pharma (ASND)
May 25, 2025 03:00PM Biotech stocks Q1 earnings review
May 20, 2025 06:00AM Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
May 20, 2025 06:00AM Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
May 13, 2025 04:02PM Ascendis Pharma (ASND) : New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CN
May 12, 2025 04:45PM Ascendis Pharma (ASND): New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
May 12, 2025 06:38AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
May 5, 2025 03:29AM Morgan Stanley Upgrades Ascendis Pharma (ASND) to Overweight
May 2, 2025 10:48AM Ascendis Pharma (ASND) PT Raised to $245 at JPMorgan
May 2, 2025 06:33AM Ascendis Pharma (ASND) PT Raised to $280 at Evercore ISI, 'remains a top pick'
May 1, 2025 04:01PM Ascendis Pharma (ASND) Misses Q1 EPS by 11c
Apr 16, 2025 06:29AM RBC Capital Starts Ascendis Pharma (ASND) at Outperform
View More Recent Stories View Older Stories